TickerGuard
Buy Day today: Poor (44) Weak market breadth · no major macro event
OCS

Oculis Holding AG

Healthcare · Biotechnology

7.50$ -1.4% vs. previous close Closing price · As of: Nov 12, 2026

Ownership

Ownership Structure

Who owns Oculis Holding AG (OCS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 92.6% of the shares are freely tradable; institutional investors hold 40.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 40.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 3.5%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 92.6%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 3.8%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 56Mio.

Largest Shareholders

Institutions

Institutions OCS
Name Stake (%) Shares Change (%) Date
EQT Fund Management S.à r.l. 11.29 6,950,294 +17.8 06/30/2026
Aberdeen Group PLC 3.51 2,159,809 +23.6 06/30/2026
Millennium Management LLC 3.32 2,042,467 +123.7 06/30/2026
Pivotal bioVenture Partners Investment Advisor LLC 2.45 1,506,250 -10.4 06/30/2026
Citadel Advisors Llc 1.60 987,204 +512.1 06/30/2026
BRAIDWELL LP 1.35 834,183 +0.0 06/30/2026
Perceptive Advisors LLC 1.31 808,827 +63.8 06/30/2026

Funds

Funds OCS
Name Stake (%) Shares Change (%) Date
HBM Healthcare Investments AG Ord 1.78 993,827 +0.0 09/30/2026
abrdn Healthcare Investors 1.54 855,885 +0.0 09/30/2026
abrdn Healthcare Opportunities 1.29 717,336 +0.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?